NCT00657995

Brief Summary

This study evaluated a closed-loop system providing continuous monitoring and strict control of perioperative blood glucose following pancreatic resection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2007

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2008

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 14, 2008

Completed
Last Updated

April 14, 2008

Status Verified

April 1, 2008

Enrollment Period

8 months

First QC Date

April 4, 2008

Last Update Submit

April 8, 2008

Conditions

Keywords

pancreatogenicdiabetesartificialpancreas

Outcome Measures

Primary Outcomes (1)

  • the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas

    the first postoperative 18 hours in the surgical intensive care unit

Secondary Outcomes (1)

  • the total amount of insulin required for glycemic control after pancreatic resection

    the first postoperative 18 hours in the surgical intensive care unit

Study Arms (1)

2

EXPERIMENTAL

Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.

Device: Artificial Pancreas (STG-22)

Interventions

safe tool

Also known as: STG-22; NIKKISO Corporation, Japan
2

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • This study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease.

You may not qualify if:

  • weight loss greater than 10% during the previous 6 months
  • signs of distant metastasis
  • respiratory, renal,or heart disease
  • Patients provided written informed consent prior to enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kochi Medical School, Kochi University

Nankoku, Kohasu-Okocho, 783-8505, Japan

Location

MeSH Terms

Conditions

Pancreatic NeoplasmsDiabetes Mellitus

Interventions

Pancreas, Artificial

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Artificial OrgansSurgical EquipmentEquipment and Supplies

Study Officials

  • Takehiro Okabayashi, MD

    Kochi Medical School, Kochi University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 4, 2008

First Posted

April 14, 2008

Study Start

April 1, 2007

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

April 14, 2008

Record last verified: 2008-04

Locations